CD20-directed Cytolytic Antibody [EPC]

188942 reported adverse events

Drugs of this class: OFATUMUMAB OBINUTUZUMAB OCRELIZUMAB RITUXIMAB RITUXIMAB AND HYALURONIDASE RITUXIMAB-ABBS RITUXIMAB-ARRX RITUXIMAB-PVVR

These side effects are most commonly reported by patients taking drugs of the CD20-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 26064
1 OFF LABEL USE 21167
2 FATIGUE 16500
3 RHEUMATOID ARTHRITIS 14315
4 PAIN 14127
5 COVID-19 9818
6 PYREXIA 9627
7 INFUSION RELATED REACTION 9428
8 ARTHRALGIA 9408
9 RASH 9208
See all common reactions for CD20-directed Cytolytic Antibody [EPC]

Drugs of the CD20-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 2790 0.8279
1 SWOLLEN JOINT COUNT INCREASED 600 0.8000
2 RED BLOOD CELL SEDIMENTATION RATE 179 0.7682
3 PEMPHIGUS 5408 0.7679
4 SARS-COV-2 ANTIBODY TEST NEGATIVE 230 0.7395
5 CHRONIC LYMPHOCYTIC LEUKAEMIA RECURRENT 316 0.6840
6 RHEUMATOID FACTOR POSITIVE 2041 0.6646
7 RHEUMATIC FEVER 694 0.6462
8 B-CELL LYMPHOMA RECURRENT 269 0.6390
9 B-LYMPHOCYTE COUNT DECREASED 468 0.6215
See all enriched reactions for CD20-directed Cytolytic Antibody [EPC]